(Q34560590)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

J F Gautier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

S Fetita

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

E Sobngwi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

C Salaün-Martin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

3 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

233-242

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

1 reference

7 January 2021

New developments in the incretin concept

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Incretins, insulin secretion and Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Is glucagon-like peptide 1 an incretin hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970190-8

7 January 2021

10.1016/S1262-3636(07)70190-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142014%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference